000			02165 a2200625 4500
005			20250515155243.0
264		0	_c20090611
008			200906s 0 0 ger d
022			_a1438-8820
024	7		_a10.1055/s-2008-1038176 _2doi
040			_aNLM _beng _cNLM
100	1		_aBolenz, C
245	0	0	_a[Medical treatment of metastatic renal cell carcinoma after the approval and market entry of multitargeted tyrosine kinase inhibitors in Germany]. _h[electronic resource]
260			_bAktuelle Urologie _cJan 2009
300			_a31-6 p. _bdigital
500			_aPublication Type: Comparative Study; Evaluation Study; Journal Article
650	0	4	_aAged
650	0	4	_aAged, 80 and over
650	0	4	_aAngiogenesis Inhibitors _xadministration & dosage
650	0	4	_aAntineoplastic Agents _xadministration & dosage
650	0	4	_aBenzenesulfonates _xadministration & dosage
650	0	4	_aCarcinoma, Renal Cell _xdrug therapy
650	0	4	_aClinical Trials, Phase III as Topic
650	0	4	_aCohort Studies
650	0	4	_aData Interpretation, Statistical
650	0	4	_aFemale
650	0	4	_aGermany
650	0	4	_aHumans
650	0	4	_aIndoles _xadministration & dosage
650	0	4	_aKidney Neoplasms _xdrug therapy
650	0	4	_aMale
650	0	4	_aMedical Oncology
650	0	4	_aMiddle Aged
650	0	4	_aNeoplasm Metastasis
650	0	4	_aNiacinamide _xanalogs & derivatives
650	0	4	_aPhenylurea Compounds
650	0	4	_aProtein Kinase Inhibitors _xadministration & dosage
650	0	4	_aProtein-Tyrosine Kinases _xantagonists & inhibitors
650	0	4	_aPyridines _xadministration & dosage
650	0	4	_aPyrroles _xadministration & dosage
650	0	4	_aSorafenib
650	0	4	_aSunitinib
650	0	4	_aSurveys and Questionnaires
650	0	4	_aTime Factors
650	0	4	_aUrology
700	1		_aTrojan, L
700	1		_aHoneck, P
700	1		_aSchöppler, G
700	1		_aHerrmann, E
700	1		_aAlken, P
700	1		_aMichel, M S
700	1		_aHäcker, A
773	0		_tAktuelle Urologie _gvol. 40 _gno. 1 _gp. 31-6
856	4	0	_uhttps://doi.org/10.1055/s-2008-1038176 _zAvailable from publisher's website
999			_c18623143 _d18623143